FSH受体基因型及其对使用可利洛特罗α进行供卵者卵巢刺激结果的影响
前瞻性队列研究纳入152个供卵者卵巢刺激周期,比较单用150微克可利洛特罗α与加用重组FSH 225 IU/d两种方案下FSHR p.N680S多态性对刺激结果的影响。SN和NN基因型供卵者获卵数及MII卵数均优于SS型,但该差异仅在单药组显著,加用重组FSH组无显著差异。作者建议对FSHR p.N680S进行基因分型以个体化治疗。
要点
- SN和NN基因型供卵者获卵数(15.78 vs 10.83)和MII卵数(12.34 vs 9.00)均高于SS型。
- 单用可利洛特罗α组中SN/NN型获卵数(13.83 vs 7.50)和MII卵数(10.24 vs 5.42)高于SS型。
- 加用重组FSH组中各基因型获卵数和MII卵数无显著差异。
核心结论
- 使用可利洛特罗α的卵巢刺激方案中,SS基因型女性可能与获卵数和MII卵数较少相关,建议对FSHR p.N680S进行基因分型以个体化治疗。
研究设计与样本
- 前瞻性队列研究,纳入152个供卵者卵巢刺激周期,组1(n=80)单用150微克可利洛特罗α,组2(n=72)加用重组FSH 225 IU/d,采用等位基因判别法对FSHR p.N680S多态性进行基因分型,线性回归分析组间差异。
主要发现
- 总体SN和NN基因型供卵者获卵数高于SS型(15.78 vs 10.83,P=0.008),MII卵数亦高于SS型(12.34 vs 9.00,P=0.032)。
- 组1中SN/NN型获卵数高于SS型(13.83 vs 7.50,P=0.018),MII卵数亦高于SS型(10.24 vs 5.42,P=0.038)。
- 组2中SN/NN型与SS型获卵数无显著差异(17.55 vs 13.06,P=0.064),MII卵数亦无显著差异(14.25 vs 11.39,P=0.12)。
临床怎么用
- 作者建议对女性FSHR p.N680S进行基因分型以指导个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does the FSH receptor (FSHR) genotype influence the results of donor ovarian stimulation using corifollitropin alfa? DESIGN: A prospective cohort study was performed including 152 oocyte donor ovarian stimulations: group 1 (n = 80) using a single dose of 150 µg of corifollitropin alpha; and group 2 (n = 72) using in addition to corifollitropin alpha, continued stimulation using recombinant FSH 225 IU daily. Allelic discrimination was used to genotype the FSHR p.N680S polymorphism. Linear regression analysis was performed to study the differences between groups. RESULTS: No differences in clinical characteristics between genotypes were reported. Overall, the results of ovarian stimulation were better in oocyte donors with SN and NN genotypes compared with SS in terms of the number of retrieved oocytes (15.78 versus 10.83; P = 0.008) and retrieved metaphase II (MII) oocytes (12.34 versus 9.00; P = 0.032). Corresponding differences were also observed in group 1 for the number of retrieved oocytes (13.83 versus 7.50, P = 0.018) and retrieved MII oocytes (10.24 versus 5.42; P = 0.038). However, in group 2 no significant differences were found for oocytes retrieved (17.55 versus 13.06, P = 0.064) or MII oocytes (14.25 versus 11.39; P = 0.12). CONCLUSIONS: This study suggests that ovarian stimulation protocols with corifollitropin alfa in women with the SS genotypes could be associated with fewer oocytes and MII oocytes retrieved. Despite the fact that corifollitropin alfa has a longer half-life, the results for the SS genotype do not match those for the other genotypes, so other factors must be involved. Therefore, to tailor treatments, it would be advisable to genotype women at p.N680S of the FSHR.
引用
- Lledó B, Ortiz JA, Hortal M, et al. FSH receptor genotype and its influence on the results of donor ovarian stimulation using corifollitropin alfa. Reprod Biomed Online. 2022. PMID: 36075849. doi:10.1016/j.rbmo.2022.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。